Meet Some of the Physicians
and Cervical Spinal Cord
Injury Patients in the
AST-OPC1 Clinical Trial
 

News Releases

Click here to sign up and receive email notifications of new press releases.

November 17, 2014
Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury

MENLO PARK, Calif., Nov. 17, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Jane S. Lebkowski, Ph.D., Asterias' President of Research and Development, will participate in a live Google Hangout session presented by the California Institute for Regenerative Medicine (CIRM) discussing the latest progress in stem cell-based therapies for spinal cord injury (SCI).

The CIRM Google Hangout session is scheduled for Tuesday, November 18, 2014, from 12:00 to 1:00pm PT (3:00 to 4:00pm ET). To access the event, please visit http://bit.ly/1sh1Dsm.

The session will include a discussion of Asterias' CIRM-funded Phase 1/2a dose escalation clinical trial for SCI. In addition to Dr. Lebkowski, participants include Roman Reed, a tireless advocate for stem cell research and SCI treatments, and Kevin Whittlesey, Ph.D., a CIRM science officer. Mr. Reed will provide the patient advocate community's perspectives, and Dr. Whittlesey will discuss other CIRM-funded research that aims to better understand SCI and to bring stem cell-based therapies to clinic trials.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company's core technologies center on pluripotent stem cells, which are characterized by the ability to become all cell types in the human body. Asterias is focused on developing therapies based on pluripotent stem cells to treat diseases or serious injuries in several medical areas where there is high unmet medical need and without adequate available therapies. Asterias' two clinical development programs, AST-OPC1 (oligodendrocyte progenitor cells) for spinal cord injuries and AST-VAC2 (antigen-presenting allogeneic dendritic cells) for lung cancer, are based on the Company's proprietary technology platforms of Pluripotent Stem Cells and Allogeneic Dendritic Cell Immunotherapy, respectively. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.  

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias' filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.

SOURCE Asterias Biotherapeutics, Inc.



Asterias Biotherapeutics Tel: (510) 456-3800